At this year's Euro PCR 2023, the results of two percutaneous renal artery denervation (RDN) studies from China were presented in the "Late Breaking Clinical Trail" session, which aroused heated debates in both academia and the industry: one of them is the "Pivotal Trial of Targeted Denervation for Hypertension" led by Professor Huo Yong of Peking University First Hospital and supported by Suzhou Xinmai Medical Device Co. (hereinafter referred to as "SMART Trial") led by Prof. Huo Yong from Peking University First Hospital and supported by Suzhou Xinmai Medical Devices Co. Ltd. (hereinafter referred to as "Miliweiye") supported the clinical trial "Effectiveness and Safety Study of Netrod-HTN Radiofrequency Denervation System". Both trials received considerable attention, and the results of the studies were positive, providing new evidence for the treatment of hypertension with RDN. The results were deemed positive because, based on the data reported by the investigators, both clinical trials met both the primary and secondary objectives of the study hypotheses. Based on the data reported by the two trials at the conference, on 29 June 2023, industry consultant CIC Consulting led the successful online live streaming of the "SMART Trial Results Interpretation Conference". The meeting was hosted by CIC Consulting, which provided an excellent sharing and interpretation of the differences between the two trials, from protocol design to clinical implementation to data collection, which are worth exploring and thinking about in depth.

In recent years, the subfield of endovascular interventions has received a lot of attention with the rapid development of neurointerventions, cardiovascular interventions and cardiac electrophysiology. However, the field of hypertension, which has the largest number of patients in the field of cardiovascular disease, a heavy burden of disease on society, and a huge potential for improvement in disease diagnosis, treatment, and control, has not received the attention it deserves. In fact, in the field of device therapy for several major chronic diseases corresponding to the cardiopulmonary system, such as hypertension, asthma, chronic obstructive pulmonary disease, and early stage tumours of the lungs, China is still in the early stages of development, and so far there is no industry leading enterprise, and there is still a huge market potential yet to be developed. Against this background, on 14 January 2023, CIC Consultants officially released the "China Hypertension and Asthma Intervention Blue Book" (hereinafter referred to as the "Blue Book"), and on 18 January, the Blue Book Interpretation Meeting, hosted by CIC Consultants, was ceremoniously held online.

With the deepening understanding of human beings themselves, the medical frontiers of diagnosis (diagnosis) diagnosis and treatment of precision stem cell technology, medical artificial intelligence and other fields have shown remarkable therapeutic potential in diagnosis and treatment. These sub-sectors are also booming with the help of both capital and technology. Highlights of the CIC Consulting live broadcast: 1. How to see the broadening of application scenarios and incremental market opportunities brought by new technologies, and how to realize the diagnosis of different indications and the empowerment of the whole treatment field? 2. What are the capital and policy actions and support in the frontier areas of innovative technologies, artificial intelligence, and data-driven healthcare services? 3. What are the most cutting-edge technology routes in the respective segments? What kind of companies and teams can lead the industry trend, seize the dividends of technology and market, and stand out from the competition in the fast iterative progress of the innovative healthcare track?